Figure 1.

Serum sTRAIL levels. No difference between two groups (P = 0.50) before bevacizumab treatment: 1.12 ± 0.04 ng/ml in metastatic colon cancer patients and 1.17 ± 0.08 ng/ml in healthy control individuals.

Bisgin et al. BMC Cancer 2012 12:58   doi:10.1186/1471-2407-12-58
Download authors' original image